摘要
目的改善住院患者的静脉输液使用情况,提高合理用药水平。方法采用PDCA循环法,从制度层面、系统层面、人员层面、管理层面制定对策并实施,以住院患者静脉输液使用率与平均每床日使用袋(瓶)数为指标评价PDCA循环实施的效果。结果我院住院患者的静脉输液使用率由PDCA循环实施前3个月的(92.58±0.11)%降至PDCA循环实施结束后3个月的(89.72±0.62)%,静脉输液平均每床日使用袋(瓶)数由5.20±0.09降至4.64±0.24(P<0.05);静脉输液使用率由PDCA循环实施前6个月的92.55%降至PDCA循环实施结束后6个月的89.98%(P<0.05),虽然静脉输液平均每床日使用袋(瓶)数由PDCA循环实施前6个月的5.36±0.26降至PDCA循环实施结束后6个月的4.97±0.39,但差异无统计学意义(P>0.05)。结论PDCA循环法能有效降低住院患者的静脉输液使用率和平均每床日使用袋(瓶)数,提高合理用药水平。
OBJECTIVE To improve the utilization rate of intravenous infusion in inpatients and enhance the level of rational drug use.METHODS PDCA cycle method was used to formulate and implement countermeasures from the aspects of institution,system,person and management.The utilization rate of intravenous infusion and the average daily number of bags(bottles)per bed for intravenous infusion were used as indicators to evaluate the implementation effect of PDCA.RESULTS The utilization rate of intravenous infusion decreased from(92.58±0.11)%3 months before PDCA cycle to(89.72±0.62)%3 months after PDCA cycle,and the average daily number of bags(bottles)per bed from intravenous infusion decreased from 5.20±0.09 to 4.64±0.24(P<0.05).The utilization rate of intravenous infusion decreased from 92.55%6 months before PDCA cycle to 89.98%6 months after PDCA cycle(P<0.05);but average daily number of bags(bottles)per bed for intravenous infusion decreased from 5.36±0.266 months before PDCA cycle to 4.97±0.396 months after PDCA cycle,without statistical significance(P>0.05).CONCLUSIONS PDCA cycle method can effectively reduce the utilization rate and average daily number of bags(bottles)per bed for intravenous infusion in the inpatients and improve the level of rational drug use.
作者
时银萍
李晓
崔学艳
黄欣
时海燕
杨依磊
韩毅
牟燕
李妍
SHI Yinping;LI Xiao;CUI Xueyan;HUANG Xin;SHI Haiyan;YANG Yilei;HAN Yi;MU Yan;LI Yan(Dept.of Clinical Pharmacy,the First Affiliated Hospital of Shandong First Medical University(Shandong Provincial Qianfoshan Hospital)/Shandong Engineering and Technology Research Center for Clinical Evaluation and R&D of Pediatric Drug/Shandong Medicine and Health Key Laboratory of Clinical Pharmacy,Jinan 250014,China)
出处
《中国药房》
CAS
北大核心
2022年第22期2797-2800,共4页
China Pharmacy
基金
国家重点研发计划项目(No.2017YFC0910000)。
